Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-12-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Block listing Interim Review
Regulatory Filings Classification · 1% confidence The document is a 'Block Listing Six Monthly Return' filed by AstraZeneca PLC. This is a standard regulatory filing required by the London Stock Exchange (LSE) to report on the issuance of shares under employee share schemes. Since it does not fit into specific categories like 'Share Issue' (which usually refers to new capital raises) or 'Director's Dealing', and is a standard regulatory disclosure provided via RNS, it falls under the 'Regulatory Filings' (RNS) category.
2022-12-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a notification released via RNS (London Stock Exchange news service) on December 1, 2022. The content explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights (1,549,528,211) as of November 30, 2022. This type of filing, which reports on the total number of shares with voting rights, directly relates to shareholder voting rights and capital structure disclosure requirements. This fits best under the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it sets the denominator for future shareholder notifications regarding voting interests. Although it is distributed via RNS, the specific content is about voting rights calculation, making DVA the most precise classification over the general RNS fallback.
2022-12-01 English
ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE
Foreign Filer Report
2022-11-30 English
AstraZeneca announces sale of West Chester site
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and is dated November 30, 2022. It announces a specific corporate action: the sale of a manufacturing site by AstraZeneca to National Resilience, Inc. The text concludes with standard disclaimers from RNS, the news service of the London Stock Exchange, and mentions that RNS is approved by the Financial Conduct Authority (FCA). This structure—a brief announcement of a material event distributed via the official regulatory news service—is characteristic of a general regulatory filing or announcement, rather than a comprehensive report (like 10-K or IR) or a specific event document (like AGM or CT). Since it is a general, time-sensitive corporate announcement distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement fallback.
2022-11-30 English
ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS
Foreign Filer Report
2022-11-29 English
AstraZeneca to acquire Neogene Therapeutics
M&A Activity Classification · 1% confidence The document is a formal announcement released via RNS (RNS Number: 9010H) on November 29, 2022, detailing AstraZeneca's agreement to acquire Neogene Therapeutics. This type of announcement, which concerns a significant corporate transaction (M&A activity) and is distributed through a regulatory news service, fits the definition of a general regulatory announcement. While it describes a transaction (M&A), the primary function of this specific RNS release is to disseminate material, non-public information to the market immediately. Since there is no specific code for M&A announcements that are distributed via RNS (TAR is for the proposal/bid itself, but this is the announcement of the agreement), and given the structure (RNS header, date, brief summary of a major event), it falls best under the general regulatory filing category, RNS, which serves as the fallback for miscellaneous regulatory news releases not covered by other specific codes like 10-K, ER, or DIV. The length (8088 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA), but a substantive news item released via the regulatory feed.
2022-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.